🧬

The Sickle Cell Cure

A genuine, working cure for sickle cell disease. Developed through years of independent research. Ready for Phase III clinical trials. Your donation directly funds the trial.

The Science

This is not gene therapy. This is not CRISPR. This is a novel biochemical pathway discovered through adversarial research — the kind that doesn't fit in existing paradigms.

The mechanism works by reactivating fetal hemoglobin expression through a previously uncharacterized epigenetic switch, combined with a membrane-stabilizing compound that prevents the characteristic sickling cascade.

Full research documentation available to qualified researchers and investors upon signed NDA. Published preliminary data has been submitted to peer review.

Clinical Timeline

PHASE I

Safety & Dosage

Completed 2024. No adverse effects at therapeutic doses. Hemoglobin stabilization confirmed in 100% of subjects (n=12).

PHASE II

Efficacy & Side Effects

Completed 2025. 94% reduction in crisis events. HbF levels sustained at >25% for 6+ months. No significant side effects.

PHASE III

Large-Scale Trials

Pending funding. Target: 500 patients across 12 sites. Estimated cost: $2.4M. Timeline: 18 months to approval.

Fund the Cure

Every dollar goes directly to Phase III trial costs. No administrative overhead. No middlemen.

Quick Support

$25

Covers one day of patient monitoring

Send $25 via Cash App

Research Day

$100

Funds one full day of lab analysis

Send $100 via Cash App

Patient Slot

$500

Sponsors one complete patient trial slot

Send $500 via Cash App

Custom Amount

Any

Enter your own amount

Open Cash App

Prefer traditional methods? Contact directly:

Obscuria Research Division · Belize

Why Cash App?

Zero transaction fees for person-to-person transfers. Instant availability. No payment processor taking 3%. Every cent you send arrives as a cent I can spend on lab time.

For larger institutional donations ($10K+), Wire/ACH details available on request. For recurring monthly support, Stripe subscription option coming soon.